A-01 Registration at the conference venue Tuesday 14:00-18:30 |
A-02 Opening ceremony and welcome reception Tuesday 19:30 |
B-01 Registration at the conference venue Wednesday 08:00-09:00 |
B-02 Welcome and Introduction Wednesday 09:00-09:15 |
B-03 Steven Kern Conducting clinical trials in challenging environments Wednesday 09:15-09:30 |
B-04 France Mentré Estimating an effective dose for a repurposed drug to treat Ebola: the case of favipiravir Wednesday 09:30-09:55 |
B-05 Matthias Machacek Estimating an effective dose for a new drug to treat Ebola with incomplete information: the case of Zmapp Wednesday 09:55-10:20 |
B-06 Scott Berry An Adaptive Platform Trial for Ebola: Application to Future Epidemics Wednesday 10:20-10:45 |
B-07 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:45-12:15 |
B-08 Roberto Bizzotto A model of glucose clearance to improve the description of glucose homeostasis Wednesday 12:15-12:35 |
B-09 Rada Savic A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin Therapy Wednesday 12:35-12:55 |
B-10 Lunch Wednesday 12:55-14:25 |
B-11 David Giltinan On the 20th anniversary of 'Nonlinear models for repeated measurement data': why write a book about PK/PD modeling? Wednesday 14:25-14:50 |
B-12 Marie Davidian On the 20th anniversary of 'Nonlinear models for repeated measurement data': Nonlinear mixed effects modeling 20 years later Wednesday 14:50-15:15 |
B-13 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:15-16:40 |
B-14 José David Gómez-Mantilla Towards Patient Stratification and Treatment in the Autoimmune Disease Lupus Erythematosus using a Systems Pharmacology approach. Wednesday 16:40-17:00 |
B-15 Gopichand Gottipati Modeling of a composite score in Parkinson’s Disease using Item Response Theory Wednesday 17:00-17:20 |
B-16 Emilie Hénin Determination of effective blood concentrations of cyclosporine in pediatric severe aplastic anemia based on a time-to-response model Wednesday 17:20-17:40 |
C-01 Huixin Yu Development of a tumour growth inhibition model to elucidate the effect of ritonavir on intratumoural metabolism and anti-tumour effect of docetaxel in a mouse model for hereditary breast cancer Thursday 09:00-09:25 |
C-02 - - Automated proper lumping for simplification of systems models Thursday 09:25-09:50 |
C-03 Adrien Tessier Modelling pharmacogenetic data in population studies during drug development Thursday 09:50-10:15 |
C-04 Presentation of Lewis Sheiner student session awards Thursday 10.15-10.20 |
C-05 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 10:20-11:45 |
C-06 Michael Betancourt Part I: Building Robust PK/PD Population Models with Bayesian Inference Thursday 11:45-12:30 |
C-07 Sebastian Weber Part II: Building Robust PK/PD Population Models with Bayesian Inference Thursday 11:45-12:30 |
C-08 Thierry Wendling Application of a Bayesian population approach to physiologically-based modelling and simulation of mavoglurant pharmacokinetics Thursday 12:30-12:50 |
C-09 Lunch Thursday 12:50-14:10 |
C-10 Rong Deng Towards Model-Based Drug Development of New Therapeutics for Hepatitis C Virus Thursday 14:10-14:30 |
C-11 Joe Standing Treating Resistant Gram-Negatives: Bedside to Bench and Back Thursday 14:30-14:50 |
C-12 Anders Kristoffersson A Pharmacokinetic-Pharmacodynamic (PKPD) Model Characterizing Resistance for Predictions of Bacterial Kill in vivo Thursday 14:50-15:10 |
C-13 Nick Holford Announcement of WCoP 2016 Thursday 15:10-15:15 |
C-14 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:15-16:30 |
C-15 Andrew Hooker Preconditioning of Nonlinear Mixed Effect models for Stabilization of the Covariance Matrix Computation Thursday 16:30-16:50 |
C-16 Eric Strömberg Simulated model based adaptive optimal design of adult to children bridging study using FDA stopping criteria. Thursday 16:50-17:10 |
C-17 Sebastian Ueckert Alternative to Resampling Methods in Maximum Likelihood Estimation for NLMEMs by Borrowing from Bayesian Methodology Thursday 17:10-17:30 |
D-01 Joel Tarning Semi-mechanistic time-to-event modelling in malaria Friday 09:15-09:35 |
D-02 Natalie Filmann Modeling the PK/PD of hepatitis B immunoglobulin after hepatitis B induced liver transplantation by an extended Target Mediated Drug Disposition Model Friday 09:35-09:55 |
D-03 Dimitra Bon Multiscale modelling for hepatitis C treatment Friday 09:55-10:15 |
D-04 Preview of PAGE2016 Friday 10.15-10.25 |
D-05 Coffee break Friday 10:25-10:55 |
D-06 Nadia Terranova Analysis of individual target lesions for tumor size models of drug resistance: a new methodology encompassing signal processing and machine learning Friday 10:55-11:15 |
D-07 Nelleke Snelder PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin – What is the optimal testosterone level? Friday 11:15-11:35 |
D-08 Anna Georgieva Kondic Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison Friday 11:35-11:55 |
D-09 Pauline Mazzocco Modeling the emergence of resistance in low-grade glioma patients treated with temozolomide, and simulations using a stochastic approach Friday 11:55-12:15 |
D-10 Closing remarks Friday 12.15-12.25 |
D-11 Audience input for potential PAGE2015 topics Friday 12:25-12:45 |
I-01 Jae Eun Ahn Modelling and Simulation of Motor Symptom Measurements in Parkinson’s Disease after L-Dopa Administration Wednesday 10:45-12:15 |
I-02 Mona Alameddine Optimal phase 2 dose selection based on the relationship between exposure and target occupancy Wednesday 10:45-12:15 |
I-03 Hesham Al-Sallami Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients Wednesday 10:45-12:15 |
I-04 Oskar Alskär Interspecies scaling of the integrated glucose insulin model Wednesday 10:45-12:15 |
I-05 Robert Andersson Dose-response-time modelling - Second generation turnover model with integral feedback control Wednesday 10:45-12:15 |
I-06 Yusuke Asai Mathematical modeling by random ordinary differential equations and their numerical schemes Wednesday 10:45-12:15 |
I-07 Hyun-moon Back A Mechanistic multicompartmental Pharmacokinetic model for food effect of fenofibrate Wednesday 10:45-12:15 |
I-08 Kathryn Ball Semi-physiological population pharmacokinetic modelling of renal transporter-mediated clinical drug-drug interactions Wednesday 10:45-12:15 |
I-09 Guillaume Baneyx Population PK model describing multiple peaks after a single oral administration of buparlisib in healthy volunteers. Wednesday 10:45-12:15 |
I-10 Charlotte Barker Population pharmacokinetics of benzylpenicillin in neonates in routine care Wednesday 10:45-12:15 |
I-11 Christian Bartels Relation of FEV1 to COPD Patient Outcomes: A patient level pooled analysis of COPD clinical trials Wednesday 10:45-12:15 |
I-12 Ana Bastos A joint population pharmacokinetic model of total and unbound temocillin serum concentrations in hemodialysis patients Wednesday 10:45-12:15 |
I-13 Stephan Benay Linear compartmental pharmacokinetic models : from continuous-time differential form to discrete time auto-regression with extra inputs. Application to system identification. Wednesday 10:45-12:15 |
I-14 Linnea Bergenholm Population PKPD modelling of QRS and PR intervals in conscious dogs. Wednesday 10:45-12:15 |
I-15 Aliénor Bergès Time-to-event (TTE) modelling in drug safety evaluation: a case study Wednesday 10:45-12:15 |
I-16 Jan Berkhout Systems pharmacology modeling describing osteoporotic disease progression in a population of postmenopausal women receiving placebo or alendronate Wednesday 10:45-12:15 |
I-17 Marival Bermejo Level A IVIVC for Carbamazepine IR formulations and in vitro dissolution specifications using one-step approaches Wednesday 10:45-12:15 |
I-18 Julie Bertrand Bayesian Variable Selection for high-throughput genetic association analysis in population pharmacokinetics. Wednesday 10:45-12:15 |
I-19 Shanshan Bi Model-Based Meta-Analysis (MBMA) for direct-acting antiviral (DAA) agents in the Treatment of Chronic HCV Wednesday 10:45-12:15 |
I-20 Andrzej Bienczak Population Pharmacokinetic/Pharmacogenetic Analysis of Nevirapine in African Children Wednesday 10:45-12:15 |
I-21 Konstantinos Biliouris MatVPC: A User-friendly Matlab Tool for the Automatic Construction of Visual Predictive Checks and Quantified Visual Predictive Checks of Systems Pharmacology Models Wednesday 10:45-12:15 |
I-22 Sofia Birgersson New micronized formulation does not affect the population pharmacokinetic properties of artemisinin. Wednesday 10:45-12:15 |
I-23 Henrik Bjugård Nyberg Influence of Covariance Step Success on Final Parameter Estimates Wednesday 10:45-12:15 |
I-24 Irina Bondareva Population modeling of changes in steady–state pharmacokinetics of carbamazepine (CBZ) due to antiepileptic drug-drug interactions from therapeutic drug monitoring (TDM) data Wednesday 10:45-12:15 |
I-25 Jennifer Bonner Building of a virtual paediatric cancer population for physiologically-based pharmacokinetic modelling and simulation in neonates, infants, and children Wednesday 10:45-12:15 |
I-26 Boram Ohk Population pharmacokinetics of Fimasartan Wednesday 10:45-12:15 |
I-27 Elisa Borella Predictive assessments of pharmacokinetic alterations in subjects with renal disease Wednesday 10:45-12:15 |
I-28 Jens Markus Borghardt A New Parameterisation to Describe Parallel Absorption Processes After Drug Inhalation Wednesday 10:45-12:15 |
I-29 Rolien Bosch A mechanism-based model is able to simultaneously explain the effect of rhLCAT and HDL mimetics on biomarkers of reverse cholesterol transport Wednesday 10:45-12:15 |
I-30 Marion Bouillon-Pichault Longitudinal Model-Based Meta-Analysis in Type 2 Diabetes: Assessment of link between fasting plasma glucose and Hba1c. Wednesday 10:45-12:15 |
I-31 Karl Brendel How to consider microdosing data in a population PK analysis? Wednesday 10:45-12:15 |
I-32 Annika Brings Modelling and simulation of adverse drug effects on heart rate in the anaesthetized mouse Wednesday 10:45-12:15 |
I-33 Jantine Brussee Population modeling of cytochrome P450 mediated drug metabolism and oral absorption in preterm neonates receiving intravenous and oral midazolam in a cross-over study Wednesday 10:45-12:15 |
I-34 Simon Buatois Using Item response theory to yield information from the MDS-UPDRS items in Parkinson’s disease clinical trials Wednesday 10:45-12:15 |
I-35 Núria Buil Bruna Population PK/PD modelling of the biomarker and progression free survival effects of Lanreotide Autogel in patients with non-functioning gastroenteropancreatic neuroendocrine tumors Wednesday 10:45-12:15 |
I-36 Theresa Cain Application of Simcyp’s R Library Package in Simulation and Prediction of Metoprolol Compliance Using a Single Plasma Concentration Sample Wednesday 10:45-12:15 |
I-37 Sophie Callies Dose projection and prediction of PK/PD response - a bench to bedside example for LY drug. Wednesday 10:45-12:15 |
I-38 Elisa Calvier Extrapolation potential of semi-physiological covariate models to newborns: a simulation-based study Wednesday 10:45-12:15 |
I-39 Tim Cardilin Modelling and Analysis of Tumor Growth Inhibition for Combination Therapy using Tumor Static Concentration Curves Wednesday 10:45-12:15 |
I-40 Letizia Carrara Modelling the effect of Sunitinib given alone and in combination with CPT-11 on the tumor growth in xenografted mice Wednesday 10:45-12:15 |
I-41 Massimo Cella Use of a TMDD model in the translational development of a BDNF-neutralizing monoclonal antibody Wednesday 10:45-12:15 |
I-42 Dong Woo Chae Mechanistic Modeling of Telmisartan Blood Pressure Lowering Effect in Human Wednesday 10:45-12:15 |
I-43 Pascal Chanu Model-based simulation assessment of Personalized Healthcare strategies. A case for siponimod in multiple sclerosis. Wednesday 10:45-12:15 |
I-44 Aziz Chaouch Approximate prediction percentiles for non-linear mixed effects models with continuous response Wednesday 10:45-12:15 |
I-45 Christophe Chassagnole Modelling Synergistic Immunotherapy Combinations with Virtual Tumour Wednesday 10:45-12:15 |
I-46 Clarisse Chavanne How to simulate pediatric pharmacokinetic (PK) exposures using a population PK dataset composed of incomplete age groups. Wednesday 10:45-12:15 |
I-47 Tina Checchio Mixed Effects Analysis of Non-compartmental Pharmacokinetic Parameters of Tofacitinib from 16 Phase 1 Studies. Wednesday 10:45-12:15 |
I-48 Pierre Chelle Assessment of Endogenous Thrombin Potential predictive potential of Thrombin Generation mechanistic models with Hemophilic A patients Wednesday 10:45-12:15 |
I-49 Chunli Chen Application of the Multistate Tuberculosis Disease Model for Studying Pharmacokinetics and Pharmacodynamics in a Chronic Tuberculosis Mouse Model Wednesday 10:45-12:15 |
I-50 Mohammed Cherkaoui Rbati Mechanistic Model to Predict DDIs in the Liver Wednesday 10:45-12:15 |
I-51 Manoranjenni Chetty Emerging covariates on the pharmacokinetics of monoclonal antibodies: Do current PBPK models account for the covariates identified in POPPK studies? Wednesday 10:45-12:15 |
I-52 Maxwell Chirehwa Model based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of first-pass hepatic extraction Wednesday 10:45-12:15 |
I-53 Jason Chittenden Evaluation of stepwise covariate model selection with Bayesian models Wednesday 10:45-12:15 |
I-54 Palang Chotsiri Population pharmacokinetic and cardiotoxic modelling of the antimalarial drug piperaquine Wednesday 10:45-12:15 |
I-55 Steve Choy Modelling the disease progression of diabetes from healthy to overtly diabetic in ZDSD rats Wednesday 10:45-12:15 |
I-56 Eirini Christodoulou Pharmacokinetics of Crocus sativus L. aqueous extract after peros and intravenous administration to C57/BL6J mice Wednesday 10:45-12:15 |
I-57 Laurent Claret A comparison of two stage and joint tumor growth inhibition-progression free survival modeling approach to simulate clinical outcome in oncology Wednesday 10:45-12:15 |
I-58 Pieter Colin Towards TDM-guided dosing for cefepime in the critically ill Wednesday 10:45-12:15 |
I-59 Francois Combes Population Pharmacodynamic Modeling and Simulation of Anti-Obesity Clinical Trials to Explore Longitudinal Weight Loss Wednesday 10:45-12:15 |
I-60 Emmanuelle Comets Joint modelling of iron and hepcidin during the menstrual cycle Wednesday 10:45-12:15 |
I-61 Ana Margarita Contreras Sandoval Towards a platform PK/PD model for an anti-PD-L1 monoclonal antibody through a preclinical syngeneic melanoma mouse model Wednesday 10:45-12:15 |
I-62 Teresa Dalla Costa Population analysis of levofloxacin in plasma, lung and prostrate measured by microdialysis in Wistar rats after intravenous and intratracheal administration Wednesday 10:45-12:15 |
I-63 André Dallmann Development of a Physiologically-Based Pharmacokinetic Population Model for Pregnant Women Wednesday 10:45-12:15 |
I-64 Adam Darwich Gastric emptying and its covariates Wednesday 10:45-12:15 |
I-65 Camila De Almeida PKPD-efficacy modelling of AZD9496, a novel oral selective estrogen receptor downregulator Wednesday 10:45-12:15 |
I-66 Pieter De Cock Population cefazolin pharmacokinetics before, during and after cardiopulmonary bypass in children undergoing cardiac surgery Wednesday 10:45-12:15 |
I-67 Sjoerd De Hoogd Population pharmacokinetics of morphine and its metabolites M3G and M6G in morbidly obese patients and healthy volunteers Wednesday 10:45-12:15 |
I-68 Mailys De Sousa Mendes Prediction of human foetal pharmacokinetic profile using transplacental parameters from ex-vivo human placenta perfusion model and pregnancy-Physiologically Based Pharmacokinetic models Wednesday 10:45-12:15 |
I-69 Elien De Thaye Model-based comparison of modified-release metoprolol formulations in beagle dogs and rabbits Wednesday 10:45-12:15 |
I-70 Femke de Velde Nonlinear absorption pharmacokinetics of amoxicillin Wednesday 10:45-12:15 |
I-71 Brenda de Winter Population pharmacokinetics of intravenous albuterol in children with status asthmaticus Wednesday 10:45-12:15 |
I-72 Willem de Winter A dynamic population PK/PD model to assess the effect of once daily versus twice daily dosing regimens on the relationship between canagliflozin plasma exposure and HbA1c response Wednesday 10:45-12:15 |
I-73 Wilbert de Witte What is the influence of diffusion-limited binding on in vivo target occupancy profiles? Wednesday 10:45-12:15 |
I-74 Francesca Del Bene Modelling potential drug-drug interaction risks with a combined top-down/bottom-up approach Wednesday 10:45-12:15 |
I-76 Paolo Denti Population Pharmacokinetics of Ofloxacin in South African children Wednesday 10:45-12:15 |
I-77 Cheikh Diack An empirical drug-disease model to characterize the effect of Ranibizumab on disease progression in wet AMD patients Wednesday 10:45-12:15 |
II-01 Emilie Schindler Comparison of item response theory and classical test theory for power/sample size for questionnaire data with various degrees of variability in items' discrimination parameters Wednesday 15:15-16:40 |
II-02 Jan-Frederik Schlender Application of an elderly PBPK model to specify age-dependent changes of active processes Wednesday 15:15-16:40 |
II-03 Henning Schmidt SBPOP/mPD: Informing dose-concentration-response relationships - Application to study design and information generation based on competitor data Wednesday 15:15-16:40 |
II-04 Rik Schoemaker PK/PD modeling of brivaracetam in epilepsy using daily seizure counts Wednesday 15:15-16:40 |
II-05 Johannes Schropp Distributed transit compartments for arbitrary lifespan distributions in aging populations Wednesday 15:15-16:40 |
II-06 Mark Sellors Reproducible Analysis Environments for Pharmacometric modelling and simulation. Wednesday 15:15-16:40 |
II-07 Marina Senek Population pharmacokinetic modelling of Levodopa/Carbidopa Microtablets versus standard formulations of Levodopa/Benserazide and Levodopa/Carbidopa Wednesday 15:15-16:40 |
II-08 Kok-Yong Seng Evaluating Ethnicity Differences in the Effect of Ritonavir, Ketoconazole and Rifampicin on Cytochrome P450 3A Induction and Inhibition in the Asian and Western Populations Wednesday 15:15-16:40 |
II-09 Seonghae Yoon Population pharmacokinetics/pharmacodynamics modeling of uric acid formation after xanthine oxidase inhibitor administrations Wednesday 15:15-16:40 |
II-10 Maria Sfouni Prediction of subtherapeutic tigecycline plasma levels by model-based Bayesian individualization Wednesday 15:15-16:40 |
II-11 Siti Maisharah Sheikh Ghadzi Disease progression in the integrated glucose-insulin model in subjects with impaired glucose tolerance Wednesday 15:15-16:40 |
II-12 Yucheng Sheng Development of a New Mixed Poisson-Gaussian Model for Count Data from Rodent Brief-Access Taste Aversion Experiments Wednesday 15:15-16:40 |
II-14 Hanna Silber Baumann Support phase II dose selection of a novel dual GIP/GLP-1agonist using a population PKPD model developed on phase I data Wednesday 15:15-16:40 |
II-15 Giovanni Smania Model-based comparison of alternative study designs in paediatric trials Wednesday 15:15-16:40 |
II-16 Byungjeong Song Application of simplified-ACAT model for specific angiotensin receptor blocker in rats to human Wednesday 15:15-16:40 |
II-17 Ivy Song Use of a Viral Dynamic Model to Evaluate Potential Dolutegravir Dosing Regimens in HIV-1 Patients with Resistance to Raltegravir and Elvitegravir Wednesday 15:15-16:40 |
II-18 Elena Soto Model informed drug discovery and development of novel treatments for hyperuricemia: from systems pharmacology to mechanistic PK/PD Wednesday 15:15-16:40 |
II-19 Rujia Xie Relationship between the Dose of Urate Lowering Therapies and Serum Uric Acid in Healthy Volunteers and Gout Patients: A Model Based Meta-Analysis (MBMA) Wednesday 15:15-16:40 |
II-20 Marios Spanakis Application of Simcyp® simulator platform for the assessment of the pharmacokinetic profile of Gd-DOTA regarding its disposition in brain tumors lesions with different vasculature Wednesday 15:15-16:40 |
II-21 Emmanouil G. Spanakis MyHealthAvatar platform: matching real life patients with the generated virtual profiles from in silico clinical trials Wednesday 15:15-16:40 |
II-22 Claudia Stötzel A Markov Chain Monte Carlo Approach to Identify Pathological Situations in the Female Menstrual Cycle Wednesday 15:15-16:40 |
II-23 Ahmed Suleiman A Modeling and Simulation Framework Characterizing the Time Courses of Adverse Events in Non-Small Cell Lung Cancer Patients Treated with Erlotinib Wednesday 15:15-16:40 |
II-24 Elin Svensson Albumin concentrations and body weight in MDR-TB patients over time on treatment and the impact on bedaquiline pharmacokinetics Wednesday 15:15-16:40 |
II-25 Robin Svensson Application of the Multistate Tuberculosis Disease Model in Rifampicin Treated Pulmonary Tuberculosis Patients Wednesday 15:15-16:40 |
II-26 Eva Sverrisdottir Modelling drug-drug interactions between morphine and methylnaltrexone Wednesday 15:15-16:40 |
II-27 Maciej Swat Standardized Output: flexible and tool-independent storage format of typical M&S results Wednesday 15:15-16:40 |
II-28 Amit Taneja Translational modelling of prolactin response following administration of D2 antagonists in rats Wednesday 15:15-16:40 |
II-29 Sonya Chapman Relative Bioavailability to Describe Variability in Exposure for an Oral Drug: A Population PK Model of Abemaciclib in Cancer Patients Wednesday 15:15-16:40 |
II-30 Max Taubert Population pharmacokinetics of linezolid in intensive care patients Wednesday 15:15-16:40 |
II-31 Paulo Teixeira Population Pharmacokinetics of Phenobarbital in Children, Adolescents and Young Adults Patients. Wednesday 15:15-16:40 |
II-32 Donato Teutonico Development of a Cardio-Vascular Systems Pharmacology Platform Wednesday 15:15-16:40 |
II-33 Hoai-Thu Thai Joint modeling of longitudinal tumor burden and time-to-event data to predict survival: application to aflibercept in second line metastatic colorectal cancer Wednesday 15:15-16:40 |
II-34 Mita Thapar Eltrombopag population pharmacokinetics-pharmacodynamics and effect on platelet counts following different regimens in Chinese adult patients with chronic primary immune thrombocytopenia Wednesday 15:15-16:40 |
II-35 Yingying Tian Physiologically based pharmacokinetic model incorporating genetic polymorphism of CYP2D6 to predict the nonlinear kinetics of paroxetine Wednesday 15:15-16:40 |
II-36 Melanie Titze PK/PD modeling of biomarker modulation and tumor growth inhibition by BI 893923, a novel IGF-1 receptor inhibitor Wednesday 15:15-16:40 |
II-37 Huybrecht T'jollyn The effect of albumin redistribution on the PK of highly bound drugs: a simulation study using the Simcyp M&S platform Wednesday 15:15-16:40 |
II-38 Mira Tout The impact of initial metabolic tumor volume on rituximab pharmacokinetics and clinical response in patients with diffuse large B-cell lymphoma Wednesday 15:15-16:40 |
II-39 Mirjam Trame Integrated Data Mining and Systems Pharmacology to Explore the Comparative Safety of Brand-Name and Generic Drugs Wednesday 15:15-16:40 |
II-40 Nikolaos Tsamandouras Application of the MCMC Bayesian estimation method in NONMEM in the context of physiologically-based pharmacokinetic modelling. Wednesday 15:15-16:40 |
II-41 Takayo Ueno Exposure-Response Analysis for Daclatasvir and Asunaprevir in Japanese Subjects with Hepatitis C Virus Infection Wednesday 15:15-16:40 |
II-42 Moreno Ursino Incorporating pharmacokinetic information in phase I studies in small populations Wednesday 15:15-16:40 |
II-43 Elodie Valade Plasma and seminal plasma population pharmacokinetics of emtricitabine and tenofovir Wednesday 15:15-16:40 |
II-44 Pyry Välitalo Morphine efficacy in mechanically ventilated preterm neonates; an item response theory analysis Wednesday 15:15-16:40 |
II-45 Sven van Dijkman Optimal dosing recommendations for combination therapy in epilepsy Wednesday 15:15-16:40 |
II-46 Anne van Rongen Population pharmacokinetics of paracetamol and glucuronide, sulphate and CYP2E1 mediated metabolites in morbidly obese patients Wednesday 15:15-16:40 |
II-47 Fiona Vanobberghen Population pharmacokinetics of tribendimidine metabolites in adults with Opisthorchis viverrini in Laos Wednesday 15:15-16:40 |
II-48 Anders Viberg A Population PK Model for Simeprevir in Healthy Volunteers and Patients Wednesday 15:15-16:40 |
II-49 Sandra Visser Translational modelling of regular human insulin pharmacokinetics and glucose dynamics in minipig and dog Wednesday 15:15-16:40 |
II-50 Swantje Völler Comparison of current dose-reduction schemes for doxorubicin in young children using a recently developed population pharmacokinetic model Wednesday 15:15-16:40 |
II-51 Johan Wallin Overall survival and change in tumor size in squamous NSCLC in relation to Necitumumab exposure Wednesday 15:15-16:40 |
II-52 Chris Walsh Use of a physiologically-based pharmacokinetic modelling and simulation approach to rationalise actinomycin D dosing in paediatric oncology Wednesday 15:15-16:40 |
II-53 Hechuan Wang An Integrated Pharmacokinetic/Viral Dynamic Model for Daclatasvir/Asunaprevir in Patients with Genotype 1 Chronic Hepatitis C Wednesday 15:15-16:40 |
II-54 Estelle Watson The population pharmacokinetics of Compound X following single and multiple intravenous infusions, to healthy subjects and subjects following surgery. Wednesday 15:15-16:40 |
II-55 Benjamin Weber New Insights in the Pulmonary Fate of Inhaled Drugs Wednesday 15:15-16:40 |
II-56 Franziska Weber Pharmacometric approach to characterize key metabolites of acetaminophen in preterm and term neonates Wednesday 15:15-16:40 |
II-57 Willi Weber PK of acetaminophen and its metabolites in preterm and term neonates using relevant external background information in a Bayesian approach with Stan Wednesday 15:15-16:40 |
II-58 Janak Wedagedera Towards more Realistic Clinical Trial Simulation: Establishing Inter-Correlations between Several Cytochrome P450 Enzyme Abundances in Human Liver Wednesday 15:15-16:40 |
II-59 Thomas Wendl A whole-body physiologically-based pharmacokinetic (PBPK) Model for Itraconazole and its metabolite to predict dynamic drug-drug-interactions Wednesday 15:15-16:40 |
II-60 Paul Westwood Population pharmacokinetic meta-analysis of ramucirumab in cancer patients Wednesday 15:15-16:40 |
II-61 Sebastian Wicha Evaluation of the delta-method to efficiently compute probability of target attainment of antibiotics Wednesday 15:15-16:40 |
II-62 Mélanie Wilbaux Semi-mechanistic model to characterize effects of gastric emptying on glucose absorption profiles in obese and non-obese adults Wednesday 15:15-16:40 |
II-63 Christian Woloch Development of a mechanistic PK/PD model to describe drug resistance using data from an in vitro dynamic PK/PD model. Wednesday 15:15-16:40 |
II-64 Dan Wright Allopurinol dosing in patients with renal impairment Wednesday 15:15-16:40 |
II-65 Kehua Wu Genome-wide interrogation of FEV1 longitudinal model in asthmatic children Wednesday 15:15-16:40 |
II-67 Christine Xu Application of physiologically based pharmacokinetic (PBPK) modeling for prediction of complex drug-drug interactions involving induction and inhibition of CYP3A4 by fedratinib Wednesday 15:15-16:40 |
II-68 Hadzliana Zainal Concentration-effect relationship of epidermal growth factor receptor inhibitor for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Wednesday 15:15-16:40 |
II-69 Stefano Zamuner Modelling development for count data: NONMEM vs R Wednesday 15:15-16:40 |
II-70 Hinojal Zazo Gómez Dosage regimen evaluation of antiretroviral gold nanoparticles using Monte Carlo Simulation Wednesday 15:15-16:40 |
II-71 Chiara Zecchin Modelling change in tumour size, survival and new lesions appearance in patients with ovarian cancer treated with carboplatin monotherapy or in combination with gemcitabine Wednesday 15:15-16:40 |
II-72 Fan Zhang Application of a mixture model to lamotrigine XR bioequivalence study Wednesday 15:15-16:40 |
II-73 Jenny zheng Could we rely on p values only for characterizing exposure response (ER) relationship by a Cox model for oncology trials? Wednesday 15:15-16:40 |
II-74 Xuan Zhou A Systems Pharmacology Model for Predicting Anticoagulant Effects of Rivaroxaban in Healthy Subjects: Assessment of Drug Pharmacokinetic and Binding Kinetic Properties Wednesday 15:15-16:40 |
II-75 Simon Zhou Complex absorption affecting terminal half-lives leading to pseudo “flip-flop” pharmacokinetics Wednesday 15:15-16:40 |
II-76 Rui Zhu Assessment of correlations between early and late efficacy endpoints to identify potential surrogacy relationships in non-Hodgkin lymphoma: a literature-based meta-analysis of 108 Phase II and Phase III studies Wednesday 15:15-16:40 |
II-77 Simbarashe Peter Zvada Population Pharmacokinetics of Efavirenz Among HIV infected South Africans Across Different Age Groups Including Pregnant Women Wednesday 15:15-16:40 |
III-01 Kristin Dickschen PBPK modeling to guide experimental design in preclinical and clinical development Thursday 10:20-11:45 |
III-02 Irene-Ariadne Kechagia A simulation study to investigate the identifiability of parameters in a minimal PBPK model structure with target binding Thursday 10:20-11:45 |
III-03 Thomas Dorlo Population pharmacokinetics and pharmacodynamics of miltefosine in mono- and combination therapy regimens for visceral leishmaniasis in East Africa Thursday 10:20-11:45 |
III-04 Anne-Gaelle Dosne Determination of Appropriate Settings in the Assessment of Parameter Uncertainty Distributions using Sampling Importance Resampling (SIR) Thursday 10:20-11:45 |
III-05 Stephen Duffull An approximation to the solution of systems of nonlinear ordinary differential equations in pharmacokinetics-pharmacodynamics Thursday 10:20-11:45 |
III-06 Sulav Duwal Systematic in silico analysis of the efficacy of NRTIs for pre-exposure prophylaxis (PrEP) against HIV-1 Thursday 10:20-11:45 |
III-07 Helena Edlund Covariate analysis of infliximab in Crohn’s disease using available PK models as prior Thursday 10:20-11:45 |
III-08 Miro Eigenmann Modeling of acquired resistance under TKI treatment Thursday 10:20-11:45 |
III-09 Rena Eudy-Byrne Sclerostin-Mediated Osteocyte Control in Bone Remodeling: Extension of a Multiscale Systems Model to Consider New Therapies for Osteoporosis Thursday 10:20-11:45 |
III-11 Gregory Ferl Mechanistic model of amyloid beta and anti-amyloid beta mAb dynamics Thursday 10:20-11:45 |
III-12 Sylvain Fouliard Interpretability is coming: using a minimal PBPK model in a population analysis Thursday 10:20-11:45 |
III-13 Linda Franken Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill patients. Thursday 10:20-11:45 |
III-15 Achim Fritsch PK/PD Modeling of Sunitinib in Patients with Metastatic Colorectal and Renal Cell Cancer Thursday 10:20-11:45 |
III-16 Aline Fuchs Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants Thursday 10:20-11:45 |
III-17 Saskia Fuhrmann Effect of mouse model immunity on antibody biodistribution Thursday 10:20-11:45 |
III-18 María García-Cremades Modelling tumour growth and survival of patients with pancreatic cancer receiving Gemcitabine Thursday 10:20-11:45 |
III-19 Charkoftaki Georgia Population pharmacokinetics of cyclophosphamide and its 4-OH metabolite in patients with glomerulonephritis Thursday 10:20-11:45 |
III-20 Eva Germovsek An Argument for Standardised Scaling: Comparison of Methods for Scaling Clearance in Children Thursday 10:20-11:45 |
III-21 Leonid Gibiansky Approximations of Target-Mediated Drug Disposition (TMDD) Equations for Systems with 1:2 and 2:1 Drug-Target Binding Stoichiometry Thursday 10:20-11:45 |
III-22 Ekaterina Gibiansky Comparison of Population Pharmacokinetics and Exposure-Response Relationships of Intravenous Rituximab and Subcutaneous Rituxumab in Patients with Chronic Lymphocytic Leukemia Thursday 10:20-11:45 |
III-23 Bojana Golubovic Population pharmacokinetic analysis of tacrolimus TDM data in stable kidney transplant patients Thursday 10:20-11:45 |
III-24 Ignacio Gonzalez-Garcia Development of a Systems Pharmacology Model for Inflammatory Bowel Disease (IBD) Thursday 10:20-11:45 |
III-25 Mario Gonzalez Sales inVentR: a new flexible, powerful and efficient R package for model drug development using NONMEM®. Thursday 10:20-11:45 |
III-26 Isabel Gonzalez-Alvarez Modelling of intestinal degradation and absorption of Clavulanic acid from In Vitro and In Situ data. Thursday 10:20-11:45 |
III-27 Verena Gotta A PK/PD meta-analysis to assess inter-study variability and translational value of preclinical exposure-QTc predictions Thursday 10:20-11:45 |
III-28 Thaddeus Grasela Toward Progressive Reporting of Modeling and Simulation Results – Part 1: Analysis of KIWI™ Metadata Thursday 10:20-11:45 |
III-29 Bruce Green Impact of Concomitant Antiretrovirals, and CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine Thursday 10:20-11:45 |
III-30 Jinju Guk Model-based assessment of risks and benefits of tissue plasminogen activator treatment in acute ischemic stroke Thursday 10:20-11:45 |
III-31 Beatriz Guglieri-Lopez A tumour growth inhibition model based on serum M-protein levels in patients with multiple myeloma treated by lenalidomide. Thursday 10:20-11:45 |
III-32 Benjamin Guiastrennec In vitro-in vivo modeling of erosion profiles for HPMC/DCP gel matrix tablets Thursday 10:20-11:45 |
III-33 Gustaf Wellhagen Quantifying drug effects in phase 2a anti-diabetic studies: Power and accuracy of four HbA1c models Thursday 10:20-11:45 |
III-34 K. Melissa Hallow Interactive evaluation of dosing regimens for a novel anti-diabetic agent: a case-study in the application of RxODE Thursday 10:20-11:45 |
III-35 Kelong Han Tumor Growth Inhibition Modeling of Onartuzumab in Combination with Erlotinib Does Not Suggest Dose Intensification Would Improve Outcome in Patients with 2nd and 3rd Line Non-small Cell Lung Cancer Thursday 10:20-11:45 |
III-36 Jacqueline Hannam A model for the respiratory effects of remifentanil and propofol during sedation and analgesia Thursday 10:20-11:45 |
III-37 Michael Heathman A Joint Concentration-Response Model for ABPM Measurements of Systolic and Diastolic Blood Pressure Thursday 10:20-11:45 |
III-38 Andrea Henrich External evaluation of a PK/PD model describing the time course of paclitaxel and neutropenia in patients with advanced non-small cell lung cancer Thursday 10:20-11:45 |
III-39 Young-A Heo Modeling of blood pressure lowering effect for co-administration of valsartan and amlodipine Thursday 10:20-11:45 |
III-40 Christoph Hethey Mechanism-based pharmacodynamic modelling of bacterial growth inhibition by antibiotics Thursday 10:20-11:45 |
III-41 Jules Heuberger Population Pharmacokinetic/Pharmacodynamic Modeling of a next generation recombinant human Factor VIIa (LR769) to Derive the Dose to be Studied in Phase 3. Thursday 10:20-11:45 |
III-42 Rollo Hoare Modelling CD4 T cell reconstitution in HIV-infected children starting antiretroviral therapy Thursday 10:20-11:45 |
III-43 Richard Höglund Artemether-lumefantrine coadministration with antiretrovirals; population pharmacokinetics and dosing implications Thursday 10:20-11:45 |
III-44 Nick Holford The Influence of Body Composition on Ethanol Pharmacokinetics using a Rate Dependent Extraction Model Thursday 10:20-11:45 |
III-45 Xiao Hu Exposure-Response Analysis of Peginterferon Beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Thursday 10:20-11:45 |
III-46 Moustafa M. A. Ibrahim Design of Phase I Studies based on Mechanism of Action of Anti-Diabetic Drugs; Assessing power, precision and accuracy in a simulation study of glucose tolerance tests Thursday 10:20-11:45 |
III-47 Itziar Irurzun-Arana Methodology for Boolean Modeling of Biological Networks Applied to Systems Pharmacology Thursday 10:20-11:45 |
III-48 Esther Janssen Population pharmacokinetic analysis of lamivudine in children aged 5 months – 18 years Thursday 10:20-11:45 |
III-49 Nerea Jauregizar Pharmacokinetic/Pharmacodynamic modeling of dynamic time-kill curves for anidulafungin against Candida Thursday 10:20-11:45 |
III-50 Shuangmin Ji Model-based Meta-analysis to Determine the Efficacy of Entecavir and Adefovir in the Treatment of Chronic Hepatitis B Thursday 10:20-11:45 |
III-51 Feng Jin Population Pharmacokinetic Modeling of Sofosbuvir, a NS5B Polymerase Inhibitor, and Its Metabolites, in Patients with Hepatitis C Virus Infection Thursday 10:20-11:45 |
III-53 Mats Jirstrand Sensitivity Equations Provide More Robust Gradients and Faster Computation of the FOCE Approximation to the Population Likelihood Thursday 10:20-11:45 |
III-54 Åsa Kragh Application of an Item Response Theory model to describe Amyotrophic Lateral Sclerosis Functional Rating Scale data Thursday 10:20-11:45 |
III-55 Francine Johansson Azeredo Comparing the fungicidal effect of free amphotericin B with to a novel miccele system against Candida albicans by a PK/PD modeling approach Thursday 10:20-11:45 |
III-56 Niclas Jonsson Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations Thursday 10:20-11:45 |
III-57 Amita Joshi Survey of methodologies for exposure-response analysis of oncology drugs approved in FDA from 2010 to 2013 Thursday 10:20-11:45 |
III-58 Marija Jovanovic Nonlinear mixed effects modelling approach in investigating amitriptyline pharmacokinetics Thursday 10:20-11:45 |
III-59 Vincent Jullien Population pharmacokinetics of bumetanide in term newborn infants with seizures Thursday 10:20-11:45 |
III-60 Rasmus Juul Kildemoes Exploring the relationship between analgesic event rate and pain intensity in kidney stone surgery: A Repeated Time to Event Pilot Study Thursday 10:20-11:45 |
III-61 Matts Kågedal Binning of exposures in survival analysis for oncology – A simulation study Thursday 10:20-11:45 |
III-62 Vangelis Karalis A computational methodology for the validation of the terminal slope estimate Thursday 10:20-11:45 |
III-63 Mats Karlsson Influence of clinical trial design to detect drug effect in systems with within subject variability Thursday 10:20-11:45 |
III-64 Evgenia Kartsaki Translating Pharmacogenomics for Personalised Medicine Thursday 10:20-11:45 |
III-65 Ron Keizer New open source R libraries for simulation and visualization: “PKPDsim” and “vpc” Thursday 10:20-11:45 |
III-66 Lena Klopp-Schulze In silico simulation study: A comparison of two population pharmacokinetic models of tamoxifen and its major metabolite endoxifen Thursday 10:20-11:45 |
III-67 Jane Knöchel Impact of randomness of mutation dynamics on the development of drug resistance under antiviral therapy Thursday 10:20-11:45 |
III-68 Gilbert Koch Model for characterizing copeptin kinetics and response in healthy volunteers Thursday 10:20-11:45 |
III-69 Stephan Koehne-Voss The impact of unmodelled interoccasion variability in bioavailability and absorption on parameter estimates in population pharmacokinetic analysis Thursday 10:20-11:45 |
III-70 Julia Korell A population pharmacokinetic model for aripiprazole and dehydro-aripiprazole Thursday 10:20-11:45 |
III-71 Wojciech Krzyzanski Physiologically structured population model (PSP) of heterogeneity of target binding to describe resistance of Gram-negative bacteria to polymyxin B (PB) Thursday 10:20-11:45 |
III-72 Anne Kuemmel Calculation of confidence and prediction intervals for pharmacokinetic and pharmacodynamic models Thursday 10:20-11:45 |
III-73 Brigitte Lacroix A time-to-event model for the immunogenicity of certolizumab pegol in rheumatoid arthritis subjects Thursday 10:20-11:45 |
III-74 Silvia Maria Lavezzi Toxicity assessment via drug-drug interaction modeling for trabectedin in patients with advanced malignancies Thursday 10:20-11:45 |
III-75 Olivia le Saux Development and validation of a model of PSA kinetics predicting prostate cancer aggressiveness during screening Thursday 10:20-11:45 |
III-76 SeungHwan Lee A population pharmacokinetic analysis of CKD-516 in patients with advanced solid tumor Thursday 10:20-11:45 |
III-77 Donghwan Lee Population pharmacokinetic analysis of Doripenem in Korean patients with acute infections Thursday 10:20-11:45 |
IV-01 Joomi Lee Population pharmacokinetic modeling and simulation of moxifloxacin in human aqueous humor after topical ocular application Thursday 15:20-16:40 |
IV-02 Diao Lei CD25 Occupancy by Daclizumab HYP in Patients with Relapsing Forms of Multiple Sclerosis Thursday 15:20-16:40 |
IV-03 Giulia Lestini Optimal design for informative protocols in xenograft tumor growth inhibition models Thursday 15:20-16:40 |
IV-04 Yan Li Characterization of the Oral Absorption Profiles of Sustained or Extended Release Formulations of Losartan, Dexibuprofen, Methylphenidate, and Tramadol Using Weibull Drug Release Functions Thursday 15:20-16:40 |
IV-05 Andreas Lindauer A two-part mixed-effects model for semi-continuous data to describe the effect of transdermal rotigotine on restless legs symptoms in adults Thursday 15:20-16:40 |
IV-06 Jos Lommerse Raltegravir dosing in neonates (IMPAACT P1110) – Use of allometry and maturation in PK modeling to develop a daily dosing regimen for investigation during the first weeks of life. Thursday 15:20-16:40 |
IV-07 Dominik Lott Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod and its primary metabolites in healthy and organ-impaired subjects Thursday 15:20-16:40 |
IV-08 Gaohua Lu Challenges in predicting the drug-drug interaction between dextromethorphan and rifampicin using a physiologically based pharmacokinetic (PBPK) model that includes three metabolites of dextromethorphan Thursday 15:20-16:40 |
IV-09 Tong Lu Clinical Trial Simulations to Assess the Probability of Revealing Biomarker Dose-Response in Ph1 Trials Thursday 15:20-16:40 |
IV-10 Paolo Magni Evaluation of software tools for Bayesian estimation on population models with count and continuous data Thursday 15:20-16:40 |
IV-11 Mats Magnusson Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation Thursday 15:20-16:40 |
IV-12 Adedeji Majekodunmi Impact of Hepatitis C coinfection on Immune reconstitution in HIV-infected children undergoing therapy Thursday 15:20-16:40 |
IV-13 Victor Mangas-Sanjuan Population PK Model of Lithium and Drug Compliance Assessment Thursday 15:20-16:40 |
IV-14 Alison Margolskee You can’t always get what you want: The (mis)use of deconvolution in IVIVC Thursday 15:20-16:40 |
IV-15 Eleonora Marostica Population PK/PD modelling of QT-interval prolongation in awake dogs and humans Thursday 15:20-16:40 |
IV-16 Lisa Martial Dose reduction of caspofungin in ICU patients with Child Pugh B will result in suboptimal exposure. Thursday 15:20-16:40 |
IV-17 Emma Martin Design of preclinical experiments: an example in chemotherapy-induced myelosupression Thursday 15:20-16:40 |
IV-18 David Mawdsley Model Based Network Meta-Analysis for Pharmacometrics and Drug-Development: a 3 year Research Collaboration between Pfizer and the University of Bristol. Thursday 15:20-16:40 |
IV-19 Osawa Mayu Population Pharmacokinetic Analysis of Daclatasvir and Asunaprevir in Japanese Subjects with Hepatitis C Virus infection Thursday 15:20-16:40 |
IV-20 Lynn McFadyen The Population Pharmacokinetics of Active Metabolites of a prodrug PF-0417132, (Dissociated Agonist of Glucocorticoid Receptor), in Rheumatoid Arthritis subjects Thursday 15:20-16:40 |
IV-21 Johanna Melin Population pharmacokinetic analysis of AZD4818 in healthy volunteers following three different routes of administration. Thursday 15:20-16:40 |
IV-22 Zhaoling Meng PK/PD modeling of recurrent events and clinical trial simulation in optimizing Phase 3 dose selection Thursday 15:20-16:40 |
IV-23 Enrica Mezzalana Integrating Target Mediated Drug Disposition (TMDD) into a minimal physiologically based modelling framework: evaluation of different quasi-steady-state approximations Thursday 15:20-16:40 |
IV-24 Robin Michelet Bioequivalence of desmopressin in children: a population pharmacokinetic study Thursday 15:20-16:40 |
IV-25 Iris Minichmayr Pharmacokinetic-pharmacodynamic target attainment of intravenous linezolid regimens in plasma and peripheral tissue fluids of four distinct populations Thursday 15:20-16:40 |
IV-26 Jonathan Mochel Evaluating the dose-response relationship of furosemide on diuresis and renin-angiotensin aldosterone activation in dogs combining multiple comparisons and modeling techniques Thursday 15:20-16:40 |
IV-27 Dirk Jan Moes Exploring risk factors for everolimus discontinuation and serious side effects in renal transplant recipients on everolimus and prednisolone dual therapy. Thursday 15:20-16:40 |
IV-28 Daniel Moj Is the ICRP reference man still suitable for physiologically-based pharmacokinetic (PBPK) modeling? Thursday 15:20-16:40 |
IV-30 Morris Muliaditan Determinants of variability in drug exposure and implications for dose selection in tuberculosis patients Thursday 15:20-16:40 |
IV-31 Helen Musther Extended Validation of a Peripheral Sampling Site in PBPK modelling using Clarithromycin, Dextromethorphan, Dextrorphan, Erythromycin, Lidocaine and Tramadol Thursday 15:20-16:40 |
IV-32 Efthymios Neroutsos Population pharmacokinetic study of Mycophenolic acid in patients with renal disease Thursday 15:20-16:40 |
IV-33 Ida Neldemo Assessment of the Predictive Properties of C-Reactive Protein and Interleukin 6 on Febrile Neutropenia Thursday 15:20-16:40 |
IV-34 Tram Nguyen Bayesian Fisher Information matrix for predicting estimation error and shrinkage of individual parameters with data below the quantification limit Thursday 15:20-16:40 |
IV-35 Elisabet Nielsen A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure Thursday 15:20-16:40 |
IV-37 Alanna Ocampo-Pelland Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D3 and its 25OHD3 Metabolite Thursday 15:20-16:40 |
IV-38 Jaeseong Oh Population pharmacokinetic analysis of fluconazole in premature infants Thursday 15:20-16:40 |
IV-39 Andrés Olivares-Morales A reduced physiologically-based pharmacokinetic (PBPK) model for the prediction of regional gastrointestinal (GI) drug absorption Thursday 15:20-16:40 |
IV-40 Edouard Ollier Clustering Absorption Profiles of Rivaroxaban Using Between Subject Model Mixture Thursday 15:20-16:40 |
IV-41 Sean Oosterholt Population pharmacokinetics of NNZ-2566 in healthy subjects and Rett syndrome patients Thursday 15:20-16:40 |
IV-42 Fernando Ortega Modelling Amyloid- ß levels in the presence of a gamma-secretase inhibitor Thursday 15:20-16:40 |
IV-43 Aziz Ouerdani Effects of Bevacizumab and Everolimus for the treatment of Vestibular Schwannomas in patients with Neurofibromatosis Type 2 Thursday 15:20-16:40 |
IV-44 Theodoros Papathanasiou Response surface analysis of synergistic interactions of morphine and gabapentin in a rat model of postoperative pain. Thursday 15:20-16:40 |
IV-45 Wansu Park Simulation of Scanning Time Point Selection for PET Scan Studies in Clinical Development of CNS Drugs: A Simple Fixed-time Design is Recommended over Scattered-time Point Designs Thursday 15:20-16:40 |
IV-46 Gab-jin Park Drug-Drug Interaction Analysis of a Drug with Long Elimination Half-life Using Population Pharmacokinetic Approach Thursday 15:20-16:40 |
IV-47 Lorenzo Pasotti Automatic translation of Bayesian pharmacometric models: the PharmML-to-WinBugs converter Thursday 15:20-16:40 |
IV-48 Devin Pastoor Standardizing and accelerating data analysis and pharmacometric workflow with the PKPDmisc R toolkit. Thursday 15:20-16:40 |
IV-49 Eleni Pefani Drop-out estimation and PKPD analysis of a Phase 2a study for an anti-IL1R1 monoclonal antibody in Chronic Obstructive Pulmonary Disease (COPD) Thursday 15:20-16:40 |
IV-50 Sophie Peigné How modelling & simulation supported the drug development in children for a drug S Thursday 15:20-16:40 |
IV-51 Christina Pentafragka Population PK/PD modeling of granocyte colony-stimulating factors given as single and repeated doses in healthy volunteers. Thursday 15:20-16:40 |
IV-52 Jonás Samuel Pérez-Blanco Age influence on clearance of phenobarbital in paediatric patients Thursday 15:20-16:40 |
IV-53 Alejandro Pérez-Pitarch Growing evidence supporting therapeutic drug monitoring of erlotinib in non-small-cell lung cancer patients: a time-to-progression model. Thursday 15:20-16:40 |
IV-54 Carlos Perez-Ruixo Platelets dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin Thursday 15:20-16:40 |
IV-55 Aurelie Petain Inter-species comparison of semi-physiological pre-clinical PK/PD models to better predict the time course of myelosuppression in human: application to a novel vectorized epipodophyllotoxin (F14512) Thursday 15:20-16:40 |
IV-56 Caroline Petit Designing a paediatric study for an antimalarial drug including prior information from adults Thursday 15:20-16:40 |
IV-57 Philippe Pierrillas Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: a novel method to handle the interval-censoring caused by experimental measurement on smaller tumor sizes Thursday 15:20-16:40 |
IV-58 Maiara Pigatto PK/PD modeling of tumor growth inhibition after etoposide administration in vitro and to tumor-bearing rats Thursday 15:20-16:40 |
IV-59 Venkatesh Pilla Reddy Modelling and simulation of concentration-depth-time profiles in the urinary bladder wall following intravesical delivery Thursday 15:20-16:40 |
IV-60 Elodie Plan Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM Thursday 15:20-16:40 |
IV-61 Daniel Polhamus Assessment of propensity score and Mahalanobis distance matching in mixed outcome data Thursday 15:20-16:40 |
IV-62 Teun Post Application of a Semi-Mechanistic, Integrated Glucose-Insulin Model to Graded Glucose Infusion Placebo Data to translate Glucose Insulin dynamics between Healthy Humans and Non-Human Primates Thursday 15:20-16:40 |
IV-63 Aurélie Premaud Mixed-effect models for longitudinal exposure to co-administered drugs and time-to-event data: prediction of risk of graft failure in renal transplant patients. Thursday 15:20-16:40 |
IV-64 Klaas Prins Acknowledging dispersion increases the power to detect central tendencies in under dispersed count data at low treatment arm size Thursday 15:20-16:40 |
IV-65 Richard Pugh The Modeling & Simulation Workbench – Enabling Model-Based Decisions in Drug Development Thursday 15:20-16:40 |
IV-66 Didier Renard Modeling of pharmacokinetic data using nonlinear mixed-effects: a paradigm shift in veterinary pharmacology. A case study with the nonsteroidal anti-inflammatory robenacoxib in cats Thursday 15:20-16:40 |
IV-67 Su-jin Rhee A population pharmacokinetic analysis of once-daily intravenous busulfan in pediatric patients undergoing hematopoietic stem cell transplantation Thursday 15:20-16:40 |
IV-68 Marie-Karelle Riviere-Jourdan Evaluation of the expected Fisher information matrix without linearization, in nonlinear mixed effect models for discrete and continuous outcomes Thursday 15:20-16:40 |
IV-69 Dirk Garmann RTTE analysis of repeated bleeding events in haemophilia A after recombinant factor VIII treatment Thursday 15:20-16:40 |
IV-70 Leire Ruiz Cerdá Systems Pharmacology Model of the Co-stimulation Process of Immune Response in Systemic Lupus Erythematosus. Thursday 15:20-16:40 |
IV-71 Alberto Russu Modelling pharmacokinetics and CSF Abeta1-40 reduction in humans after dosing with JNJ-54861911, a novel oral BACE inhibitor Thursday 15:20-16:40 |
IV-72 Yevgen Ryeznik Adaptive designs for dose finding clinical trials with time-to-event outcomes Thursday 15:20-16:40 |
IV-73 Muhammad Waqas Sadiq A whole-body physiologically based pharmacokinetic (WBPBPK) model of ciprofloxacin for prediction of bacterial killing at the site of infection Thursday 15:20-16:40 |
IV-74 Tarjinder Sahota Efficient argument settings for NONMEM 7 expectation maximisation methods Thursday 15:20-16:40 |
IV-75 Maria Luisa Sardu Xenograft experiments: assessing consistency between a drug-driven and a biomarker-driven tumor growth inhibition model Thursday 15:20-16:40 |
IV-77 Franziska Schädeli Stark Use of PBPK information to select the doses and criteria for early dose confirmation or adjustment with a minimum number of subjects in a pediatric proof of concept (POC) study Thursday 15:20-16:40 |
S-01 Sebastian Wicha TDMx: A web-application for therapeutic drug monitoring enhanced by pharmacometrics During entire meeting |
S-02 Ruben Faelens Simulo: a new PK-PD-Disease model simulator During entire meeting |